Intrathecal Riluzole not checked

Brain Trust Bio

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Intrathecal infusion of riluzole for 6 weeks followed by 6 months treatment with safety committee approval.”In the company’s words, NCT07093268 on ClinicalTrials.gov
Tested for
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Main trialPhase 1
“The purpose of this study is to investigate the safety and tolerability of intrathecal riluzole in adults with amyotrophic lateral sclerosis.”In the company’s words, NCT07093268 on ClinicalTrials.gov

Other drugs for Amyotrophic Lateral Sclerosis

All 48 drugs for Amyotrophic Lateral Sclerosis

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Not yet recruiting 15 Jun 2026 Safety of Intrathecal Riluzole in Patients With Amyotrophic Lateral Sclerosis
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Intrathecal Riluzole

Following is part of Solo: you see every change to Intrathecal Riluzole the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in